Capecitabine, an anticancer prodrug, is thought to be biotransformed into active 5-fluorouracil (5-FU) by three enzymes. Footnotes
As with other cytotoxic drugs, the interpatient variability of the pharmacokinetic parameters of capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine and fluorouracil, is high (27 to 89%) and is likely to be primarily due to variability in the activity of the enzymes involved in capecitabine metabolism
The studies presented here were undertaken to test the hypothesis that gene expression
While pharmacokinetic parameters of capecitabine in the liver did not vary significantly as a function of dosing time , its metabolism into 5′DFUR and 5-FU was the
The aim of this study was to develop a method for quantified localised detection of fluorinated compounds in human liver
The level of expression of capecitabine-metabolising enzymes might influence the extent of